American CryoStem Announces Agreement With the nanoRANCH Division of UHV Technologies for Cancer Research Utilizing ATCELL(TM...
June 18 2014 - 9:00AM
American CryoStem Corporation (OTCQB:CRYO), a
leading strategic developer, marketer and global licensor of
patented adipose tissue-based cellular technologies for the
Regenerative and Personalized Medicine industries, today announced
that the Company has entered into initial agreements with the
nanoRANCH Division of UHV Technologies, Inc. ("nanoRANCH") for the
development of methods for the delivery of therapeutics and drugs
focused upon cancer treatments utilizing adipose derived adult stem
cells. The Company will be working with Dan Dimitrijevich, PhD to
create new treatment delivery methods utilizing a combination of
nanoRANCH unique technology and CRYO's clinically processed
ATCELLs™.
The Company's research collaboration into cancer research and
cancer related applications utilizing CRYO's clinically processed
ATCELL™ products further expands relationships and potential
applications to treat a wide range of diseases in the growing
regenerative and therapeutic cellular therapy markets.
"We are noticing a sharp increase in demand for our cutting edge
clinically prepared cells and ancillary products for use in
scientific development." said Anthony Dudzinski, "further we
believe that the repeatable results that can be achieved with our
ATCELL™ products are important to the development of the
comparative data necessary to advance the use of adipose derived
stem cells in regenerative medicine and cellular therapies."
"Accurate targeting of pharmaceuticals is a continuing hurdle in
drug delivery and particularly important are selectivity and
specificity of anticancer agents." According to Dr. Dan
Dimitrijevich of nanoRANCH, "There is much to be learned from
the trafficking and homing properties of immune system cells and
stem cells as they navigate through the body. We are very fortunate
to have available from American CryoStem, ATCELL™, well defined and
characterized stem cells that will serve as an excellent model
system."
About UHV Technologies
UHV Technologies is a, high-tech nanotechnology company focused
on the development of advanced materials and devices, including
vacuum coating equipment, carbon nanotube coatings, nanocrystalline
coatings, fiber optical coating, nano-material-based devices, and
nano-biotechnology devices. Recently, UHV's other division nanoXRF
merged with MICROMATTER of Vancouver, BC to become the leading
supplier of X-Ray fluorescence calibration standards for air
pollution monitoring and diamond foils for applications in particle
and accelerator physics including cyclotrons used for production of
radiopharmaceuticals used in radiation therapy of cancer patients.
Over the past several years, UHV has been developing X-ray
fluorescence spectrometry for biological applications specifically
as it pertains to cancer diagnoses and determination of cancer
progression. Currently, UHV is funded by US Department of Energy
with three separate R&D contracts related to XRF technology for
developing products for high speed automated aluminum alloy scrap
sorting, continuous monitoring of mercury emissions from coal power
plants, and nano-crystalline foils for DOE's high energy physics
labs as well commercial applications in low energy x-ray windows.
For more information, please visit
www.nanoRANCH.com,
www.nanoXRF.com and
www.micromatter.com.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized
Medicine, American CryoStem is a developer, marketer and global
licensor of patented adipose tissue based cellular technologies and
related proprietary services with a focus on clinical processing,
commercial bio-banking and application development for adipose
(fat) tissue and autologous adipose-derived regenerative cells
(ADRCs). The Company maintains a strategic portfolio of
intellectual property and patent applications that form its Adipose
Tissue Processing Platform, which supports and promotes a growing
pipeline of biologic products and processes, clinical services and
international licensing opportunities. Through its ACS Laboratories
division, the Company operates an FDA registered, cGMP compliant
human tissue processing, cryo-storage and cell culture and
differentiation media development facility in Mount Laurel, New
Jersey. For more information, please visit
www.americancryostem.com and
www.acslaboratories.com.
CONTACT: FOR MORE INFORMATION:
732-747-1007
info@americancryostem.com
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Jul 2024 to Aug 2024
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Aug 2023 to Aug 2024